Neuropeptide Y (NPY) and norepinephrine are released together on sympathetic activation. To compare the time courses of NPY and norepinephrine washout from cardiac tissues, we measured the overflow of NPY-like immunoreactivity (NPY-LI) and norepinephrine in coronary sinus blood before, during, and after 3-minute trains of ansae subclaviae stimulation in 13 anesthetized dogs. We also measured vagally induced cardiac cycle length responses before and after ansae stimulation. Ansae stimulation increased NPY-LI and norepinephrine overflow from the heart in a frequency-dependent manner (p<0.02). After stimulation of the ansae at 5 and 10 Hz, the peak norepinephrine overflows decayed by 90%o within 2 minutes, but the NPY-LI overflows required 17±t11 and 35±21 minutes, respectively, to decay by 90%o. Cardiac vagal effects were inhibited after 5-and 10-Hz ansae stimulations, and the peak inhibitions decayed by 90%o after 19±7 and 39±t16 minutes, respectively. The 90% decay times of the NPY-LI overflows were longer (p<0.003) than those of the norepinephrine overflows but did not differ significantly (p>0.4) from the 90%o decay times of the inhibition of vagal effects. We characterized NPY-LI in coronary sinus and arterial plasma by reversed-phase high-performance liquid chromatography. Before ansae stimulation, the main peak of NPY-LI in the plasma had a retention time similar to that of the oxidized human NPY-(1-36) standard. During ansae stimulation, however, there was a substantial increase in the peak of NPY-LI that eluted in a position similar to that of the nonoxidized human NPY-(1-36) standard. These data support the hypothesis that neurally released NPY mediates the sympathetically evoked inhibition of vagal effects and indicate that the time course of removal of NPY from the heart differs substantially from that of norepinephrine. Moreover, under basal conditions, most NPY in the circulation is present in the oxidized form or as a fragment of the 36-amino-acid peptide. In contrast, cardiac sympathetic stimulation evokes the overflow of nonoxidized NPY-(1-36) into the coronary sinus plasma. (Circulation Research 1991;69:455-465) N europeptide Y (NPY) directly or indirectly affects various cardiovascular processes. NPY increases coronary and peripheral vascular resistance, independently of a-adrenergic receptor mechanisms, and potentiates norepinephrine-induced vasoconstriction in many vascular beds and isolated vessels.1-6 NPY also modulates cardiovascular function by attenuating the release of acetylcholine and norepinephrine from autonomic nerve terminals.6-8 Indeed, NPY persistently inhibits the
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The purpose of our study was to examine the time course of washout of the sympathetic stimulationevoked release of NPY from the heart. We compared the time course of its washout with that of norepi-nephrine and with the sympathetically evoked inhibition of the vagal effects on cardiac cycle length. We used reversed-phase high-performance liquid chromatography (HPLC) combined with radioimmunoassay (RIA) to characterize the NPY in dog plasma before, during, and after ansae subclaviae stimulation.
Materials and Methods Preparation
Thirteen mongrel dogs (18-28 kg) were premedicated with morphine sulfate (2 mg/kg i.m.) and anesthetized 30 minutes later with a-chloralose (100 mg/kg i.v.). A fluid-filled cannula was inserted into the left femoral vein for the administration of supplemental doses of a-chloralose (20 mg/kg/hr) and to maintain fluid balance. A fluid-filled cannula was inserted into the left femoral artery and advanced into the descending aorta. We used this cannula to collect arterial blood samples and to record arterial pressure (Statham transducer, model P23AC). A tracheal cannula was inserted, and the lungs were ventilated with air at positive pressure (animal respirator, Harvard Apparatus, South Natick, Mass.). The right and left cervical vagi were isolated, doubly ligated, and transected. A bipolar hook electrode, insulated except for the tips, was inserted into the cardiac end of the right vagus. The electrode wires were connected to a Model SD9 stimulator (Grass Instrument Co., Quincy, Mass.).
The chest was opened transversely at the fourth intercostal space. The left and right stellate ganglia were isolated, doubly ligated, and transected. The left and right ansae subclaviae were placed over individual bipolar stimulating electrodes (Harvard Apparatus). The electrode wires from the right and left ansae electrodes were connected in parallel to a stimulator (Grass model SD9).
Before the coronary sinus was cannulated, heparin (200 units/kg i.v.) was administered. The azygos vein was doubly ligated and transected. A flanged cannula was inserted into the azygos vein and threaded through the right atrium into the coronary sinus. The cannula was stabilized by passing a suture through the atrial wall and around the cannula. The suture then was ligated to hold the cannula in place. The coronary sinus outflow was diverted into the right jugular vein. To measure coronary sinus blood flow, an electromagnetic flowmeter probe was placed in the tubing that connected the coronary sinus cannula to the cannula in the jugular vein. A bipolar electrode was sutured to the right atrial appendage to record an atrial electrogram.
The right atrial electrogram, coronary sinus blood flow, arterial pressure, and AA interval (cardiac cycle length) were recorded continuously on an electrostatic recorder (model RS 1000, Gould Instruments, Cleveland, Ohio) and displayed on a Model V1000 Gould monitor. The AA interval was derived from the atrial electrogram by an analog interval meter that was accurate to within 1 msec.
Experimental Protocols
Sympathetic stimulation. The ansae subclaviae were stimulated bilaterally. We applied supramaximal stimulation (10-15 V, 1-msec pulse width) for a train duration of 3 minutes at frequencies of 5 and 10 Hz. Nine animals were used for the initial study of norepinephrine and NPY overflow. In four animals, we applied only the 10-Hz train of ansae stimulation, and in five animals, we applied both the 5-and 10-Hz trains of ansae stimulation. In the latter group, the two stimulation frequencies were applied in random order, and the stimulations were separated by 90-120 minutes. Two animals were instrumented for sham ansae stimulations, and in two additional animals, plasma samples were collected before, during, and after a 3-minute train of 10-Hz ansae stimulation for characterization of NPY-like immunoreactivity (NPY-LI) by reversed-phase HPLC.
Vagal stimulation. Before ansae stimulation, we adjusted the frequency of right vagal stimulation to increase the cardiac cycle length by approximately 100%. This frequency then was used for the remainder of the experiment. The vagus was stimulated for a train duration of 15 seconds every 2-4 minutes before and after ansae stimulation. The vagal stimuli were supramaximal (3-5 V, 1-msec pulse width), and the frequencies applied varied between 1.5 and 5.5 Hz in the individual animals.
Norepinephrine assay. For the measurement of plasma norepinephrine concentrations, we collected arterial and coronary sinus blood samples (4 ml) in prechilled tubes containing 5 mg Na2EDTA. The plasma samples were obtained from four dogs in response to only the 10-Hz ansae stimulation and from four dogs in response to both 5-and 10-Hz ansae stimulations. The plasma was separated by centrifugation (3,000 rpm, 15 minutes, 4°C) and stored at -20°C until assayed. The plasma norepinephrine content was determined by reversed-phase HPLC (model 500, Varian Associates Inc., Sunnyvale, Calif.) with electrochemical detection (model LC-17, Bioanalytical Systems, Inc., West Lafayette, Ind.). 15 Neuropeptide Y radioimmunoassay. The NPY RIA was developed according to the method of Allen et al. 16 Arterial and coronary sinus blood samples (6 ml) were collected in prechilled tubes containing heparin (20 units/ml blood) and aprotinin (50 kallikrein inhibiting units/ml blood). The plasma was separated by centrifugation and was stored at -20°C until assayed. To separate NPY from other plasma proteins, the plasma samples (2 ml) were applied to activated C18 Sep-Pak cartridges (Waters Chromatography Div., Millipore Corp., Milford, Mass.), washed with distilled water (10 ml), and eluted with 60% acetonitrile (5 ml). The eluate was dried in a SpeedVac concentrator (Savant Instruments, Inc., Hicksville, N.Y.). To determine radiolabeled peptide recovery,`251-NPY (600 cpm) was added to plasma samples before extraction. The recovery was 76.0±5.7% (n=92; mean+SEM).
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Dried samples were reconstituted in 1-2 ml assay buffer (pH 7.4) at 4°C. The assay buffer contained per liter: 8.52 g Na2HPO4, 0.826 g KH2P04, 3 .72 g Na2H2EDTA, and 0.5 g NaN3. Bovine serum albumin (1%) was added just before the assay buffer was used.
For the RIA, duplicate 50-, 100-, and 200-,l aliquots of the reconstituted sample were transferred to prechilled (4°C) tubes containing 350, 300, and 200 gl assay buffer, respectively. A 100-gl aliquot of antiserum (RAS 7172N rabbit anti-porcine NPY; Peninsula Laboratories, Inc., Belmont, Calif.) in a final dilution of 1:36,000 then was added to each tube. After a 24-hour incubation at 4°C, a 100-gl aliquot of 1251-NPY (1211-Bolton Hunter label Lys4 NPY [porcine]; New England Nuclear, Boston) containing 5,000 counts/100 gl was added to each tube, followed by a second 24-hour incubation at 4°C. Bound and free NPY were separated by the addition of a suspension of activated charcoal (1 ml). The suspension contained per 100 ml assay buffer 0.4 g activated charcoal (untreated powder, 100-400 mesh, Sigma Chemical Co., St. Louis, Mo.) and 0.04 g dextran (clinical grade, Sigma). After centrifugation (3,000 rpm, 20 minutes, 4°C), the supernatant was decanted. The bound 125I-NPY in the supernatant was measured with a gamma counter (ApexMicromedic Systems, Inc., Huntsville, Ala.). Synthetic porcine NPY-(1-36) was used as a standard in serial dilutions of 2-1,000 pg/tube.
Neuropeptide Y chromatography. Plasma samples (2-4 ml) collected before, during, and after a 3-minute train of 10-Hz ansae stimulation in two animals were extracted on C18 cartridges as described above. The dried samples were dissolved in 40% mobile phase B (80% acetonitrile/0.13% heptafluorobutyric acid) and separated on a 2150 gradient system (Pharmacia LKB Biotechnology, Piscataway, N.J.) with a C18 column (4.6x 150 mm; Vydac, Hesperia, Calif.) and a C4 guard column (Brownlee Newguard, Applied Biosystems, Foster City, Calif.).17 The system was equilibrated with 60% mobile phase A (0.13% heptafluorobutyric acid) and 40%
mobile phase B at a flow rate of 1 ml/min. 
Calculations and Statistical Analysis
We calculated the overflow of both NPY-LI and norepinephrine from the heart by subtracting the arterial concentration from the coronary sinus concentration and multiplying the difference by the coronary sinus blood flow. The coronary sinus-arterial concentration difference represents the net result of extraction and release of a substance by the heart. Because norepinephrine is extracted by the heart,19 our calculation of the norepinephrine overflow underestimates the true norepinephrine overflow. In contrast to norepinephrine, the heart does not extract appreciable quantities of NPY from the blood.2o
The data were analyzed by one-way or two-way repeated measures Figure 1 shows mean values of norepinephrine ( Figure 1A ) and NPY-LI ( Figure 1B) tion was stopped, norepinephrine overflow returned to basal levels within 5 minutes ( Figure 1A ). In contrast, NPY-LI overflow remained significantly above (p<0.01) the basal NPY-LI overflow until 60 minutes after ansae stimulation ( Figure 1B ). Figure 1C shows the time course of recovery of the vagal effects on cardiac cycle length after ansae stimulation. Before ansae stimulation, right vagal stimulation increased cardiac cycle length by 657±26 msec from a control of 503+f 15 msec (n=9). In contrast, 4 minutes after ansae stimulation, an identical vagal stimulation increased cycle length by 256±33 msec from a control of 472±13 msec. Thus, the vagally induced cycle length response was inhibited by 61±6% 4 minutes after ansae stimulation ( Figure 1C ). The vagal effects on cycle length returned slowly to control over 60 minutes. Note that the time course of the inhibition of vagal effects was similar in duration to that of the NPY-LI overflow after ansae stimulation ( Figures 1B and 1C) . Table 1 summarizes the times for the peak values of NPY-LI overflow, norepinephrine overflow, and inhibition of vagal effects to decay by 50% and 90% after the cessation of 3-minute trains of 5-and 10-Hz ansae stimulation. The times to 90% decay of the peak NPY-LI overflows evoked by the 5-and 10-Hz ansae stimulations were significantly longer than those for the norepinephrine overflows. In contrast, the times for the peak NPY-LI overflow and for the inhibition of the vagal effects to decay by 90% were not significantly different. The times for the NPY-LI overflow to decay by 50% were shorter than those for the inhibition of vagal effects to decay by 50%, but the difference was significant only after the 10-Hz ansae stimulation. After both the 5-and 10--Hz trains of ansae stimulation, the peak norepinephrine overflow decayed by 50% within 30 seconds. Because plasma samples were not obtained before 30 seconds, the times to 50% decay of the norepinephrine overflow could not be compared statistically with the times to 50% decay of the NPY-LI overflow or vagal inhibition. It is evident, however, that the times to 50% decay of the peak NPY-LI overflow and inhibition of vagal effects were much longer than 30 seconds after both the 5-and 10-Hz ansae stimulations.
Frequency Dependence of NPY-LI Overflow, Norepinephrine Overflow, and Inhibition of Vagal Effects Evoked by Ansae Subclaviae Stimulation Figure 2 shows the mean values of NPY-LI overflow in five animals before, during, and after 3-minute trains of 5-and 10-Hz ansae stimulation. The NPY-LI overflow evoked by the 10-Hz ansae stimulation was greater (p<0.001) than that evoked by the 5-Hz ansae stimulation, both during and after the cessation of ansae stimulation. The time to 90% decay of the peak NPY-LI overflow was longer (p=0.02) after the 10-Hz than after the 5-Hz ansae stimulation, but the times to 50% decay were not significantly different (Table 1) . Figure 3 shows the mean values (n=4) of norepinephrine overflow measured before, during, and after 3-minute trains of 5-and 10-Hz ansae stimulation. The norepinephrine overflow was significantly greater (p=0.02) during the 10-Hz than during the 5-Hz ansae stimulation ( Figure 3, shaded area) . After the 5-and 10-Hz ansae stimulations were stopped, however, the norepinephrine overflows into the coronary sinus blood were not significantly different (p=0.6). The times to 90% decay of the peak norepinephrine overflows after the 5-and 10-Hz ansae stimulations also were not significantly different ( Table 1) . The summary data (n=5) in Figure 4 show the time courses of the inhibition of vagal effects on cardiac cycle length after the cessation of 3-minute trains of 5-and 10-Hz ansae stimulation. The magnitude of the inhibition of vagal effects was greater (p=0.02) after the 10-Hz than after the 5-Hz ansae stimulation. Although the times for the peak vagal inhibition to decay by 50% were not significantly different after the 5-and 10-Hz ansae stimulations, the time to 90% decay was longer (p =0.02) after the 10-Hz than after the 5-Hz stimulation (Table 1) . FIGURE 3 . Norepinephrine (NE) overflowfrom heart before, during (shaded area), and after 3-minute trains of 5-and 10-Hz ansae stimulation. NE overflow was significantly greater during the 10-Hz than during the 5-Hz ansae stimulation. After ansae stimulation was stopped, NE overflows were not significantly different. Symbols represent means (n=4). Norepinephrine and NPY-LI Concentrations in the Coronary Sinus and Arterial Plasma To calculate NPY-LI and norepinephrine overflow from the heart, we subtracted the arterial concentrations of these substances from their respective coronary sinus concentrations. The venous-arterial concentration difference then was multiplied by the coronary sinus blood flow. The 3-minute trains of ansae stimulation evoked increases in norepinephrine and NPY-LI concentrations in both the coronary sinus and arterial plasma. However, the pattern of change in the plasma concentration of NPY-LI differed substantially from that of norepinephrine. During a 5-Hz ansae stimulation, for example, the coronary sinus concentration of norepinephrine increased to 10±2 ng/ml from a control of 1.1±0.2 ng/ml, and the arterial concentration increased to 2.8±0.5 ng/ml from a control of 1 Figure 6 shows the NPY-LI concentration in coronary sinus and arterial plasma before, during, and for 75 minutes after the sham ansae stimulations in both animals. Although the basal plasma concentrations of NPY-LI differed in the two animals, the concentration of NPY-LI in coronary sinus and arterial plasma did not change appreciably for more than 80 minutes in either animal.
Chromatographic Characterization of Plasma NPY-LI
We characterized NPY-LI in coronary sinus and arterial plasma in two animals by reversed-phase HPLC. Figure 7 shows the elution profiles of standards and samples separated with a 24-minute elution gradient, and Figure 8 Figures  7C-7J show the elution profiles of NPY-LI in coronary sinus and arterial plasma collected before, during, and at 10 and 60 minutes after the cessation of a 3-minute train of 10-Hz ansae stimulation in one animal. The main peak of NPY-LI in coronary sinus and arterial plasma collected before ansae stimulation ( Figures 7C and 7D ) had a retention time of 9.2-9.6 minutes, which is similar to that of the oxidized human NPY-(1-36) standard (represented by the arrow in Figures 7A and 7B ). Note also that this retention time falls between that of the synthetic NPY fragments NPY-(20-36) and NPY-(22-36). The control elution profiles ( Figures 7C and 7D ) also contained minor NPY-LI peaks that eluted with retention times of 2.4 and 16 minutes. In the plasma collected during ansae stimulation ( Figures 7E and  7F) , there was a substantial increase in the peak of NPY-LI that eluted with a retention time of 16 minutes. This retention time is similar to the retention time of the nonoxidized human NPY-(1-36) standard (i.e., 16 .5 minutes; Figures 7A and 7B) . Note that the peaks of NPY-LI with retention times of 2.4 and 9.6 minutes also were present in the plasma collected during ansae stimulation ( Figures  7E and 7F) . The elution profiles of NPY-LI in coronary sinus and arterial plasma collected 10 and 60 minutes after the cessation of ansae stimulation ( Figures 7G-7J ) each contained the three NPY-LI peaks. Figure 8 shows the elution profiles of NPY-LI in coronary sinus plasma samples collected from an additional animal. The coronary sinus plasma was collected before, during, and at 20 and 40 minutes after a 3-minute train of 10-Hz ansae stimulation. In Figure 8 , the standards and samples were separated by HPLC with a 20-minute gradient of 40-47% mobile phase B. Although the absolute retention times of the standards in Figure 8A differ from those in Figure 7A (because of differences in gradient elution times), the elution profiles of NPY-LI in coronary sinus plasma are qualitatively similar. Thus, before ansae stimulation (Figure 8B ), the main peak of NPY-LI eluted in a position similar to that of the oxidized human NPY-(1-36) standard. During ansae stimulation ( Figure 8C ), however, there was a substantial increase in the NPY-LI component that eluted with a retention time similar to that of the nonoxidized human NPY-(1-36) standard. Indeed, in this animal, the main NPY-LI component in the coronary sinus plasma collected during ansae stimulation eluted in a position similar to that of the nonoxidized human NPY-(1-36) standard.
Discussion
Our data show that in the anesthetized dog, ansae subclaviae stimulation evoked NPY-LI and norepinephrine overflow from the heart in a frequencydependent manner. After the termination of ansae stimulation, the washout of NPY-LI from the heart occurred over a significantly longer time course than the washout of norepinephrine. However, the duration of the inhibition of vagal effects was similar to the duration of the NPY-LI overflow evoked by ansae stimulation. The HPLC characterization of NPY-LI suggests that before ansae stimulation, most of the NPY-LI in the blood represents oxidized NPY-(1-36) or a fragment of the 36-amino-acid NPY molecule. However, during ansae stimulation, nonoxidized NPY-(1-36) is released from cardiac sympathetic nerve terminals, and its concentration increases in the coronary sinus and arterial plasma. Our HPLC data suggest further that the amino acid sequence of dog NPY-(1-36), which has not been determined, is similar to that of human NPY-(1-36). The amino acid sequence of human NPY-(1-36) differs from that of porcine NPY-(1-36) by containing a methionine rather than a leucine residue at position 17.18,22,23 Our data on the frequency-dependent release of norepinephrine and NPY-LI agree with previous data which showed that norepinephrine and NPY-LI are released together on sympathetic stimulation from various tissues, including the in situ guinea pig heart and the isolated pig spleen.7'24 These and other studies have shown that in response to sympathetic activation the maximum concentration or overflow of NPY-LI in venous effluent lags the norepinephrine concentration or overflow by 1-5 minutes. Our data also show that the time course of NPY-LI washout from the heart is significantly longer than that of norepinephrine (Table 1) . It has been hypothesized that the slower washout of NPY-LI than of norepinephrine from various tissues is in part due to Although the total time course of NPY-LI washout from the heart was significantly longer than that of norepinephrine, the maximum overflow of NPY-LI occurred by 30 seconds after the ansae stimulations (Figures 1 and 2) . Moreover, the peak overflows of NPY-LI decayed by 50% within 5 minutes of the cessation of the 5-and 10-Hz ansae stimulations (Table 1 ). These data indicate that an appreciable amount of the neurally released NPY was removed rapidly from the cardiac neuroeffector junctions to the coronary sinus blood. Other evidence suggests that NPY also moves readily from the blood to the cardiac neuroeffector junction.10'30 Indeed, in the anesthetized dog, intravenously administered NPY inhibits the vagally induced cardiac responses within 1 minute. 10, 30 Although much of the NPY-LI was washed out of the heart within 5 minutes of the cessation of ansae stimulation, the NPY-LI overflow remained significantly above control values for up to 40 minutes (Figures 1 and 2 ). These data suggest that some of the NPY released on sympathetic activation remained within the cardiac interstitium for a substantial period of time. The evidence presented above, however, suggests that NPY can move readily from the cardiac neuroeffector junction to the blood. Thus, it is unlikely that the prolonged time course of NPY-LI overflow from the heart can be attributed solely to the diffusion properties of this molecule. Perhaps the NPY only slowly dissociates from specific NPY receptor binding sites or from other nonspecific binding sites in the cardiac interstitium. These or other mechanisms may be responsible for the sustained NPY-LI overflow from the heart. In addition to the prolonged time course of NPY-LI overflow from the heart, we also found that the NPY-LI concentration in the blood was significantly elevated above basal levels up to 60 minutes after ansae stimulation ( Figure 5 ). At this time, however, there was no significant NPY-LI overflow from the heart. Prolonged increases in the plasma level of NPY-LI also were observed after splenic nerve stimulation in the conscious calf, after the cessation of exercise in humans, and after an increase in intracranial pressure in anesthetized pigs."120'3' Indeed, Pernow et al"l showed that after exercise in humans, the norepinephrine concentration in the venous plasma returned to basal levels within 10 minutes, whereas the NPY-LI concentration was significantly greater than its basal value for 45 minutes. The plasma half-life of exogenous NPY in the circulation has been estimated as 5 Little is known about the mechanisms by which NPY is metabolized or inactivated after its release from sympathetic nerve endings. Our data indicate, however, that after entering blood, NPY may be oxidized or degraded into fragments. Indeed, before and from 10 to 60 minutes after ansae stimulation (Figures 7 and 8) , a major NPY-LI component in plasma was eluted with a retention time similar to that of the oxidized human NPY-(1-36) standard. It has been shown that human NPY-(1-36), which has a methionine residue at position 17, is prone to oxidation.18,32 This unknown peak of NPY-LI in our dog plasma also may represent a fragment of NPY, because its retention time was between the retention times of the NPY-(20-36) and NPY-(22-36) standards. Analysis of the amino acid sequence of this peak would discriminate between these two possibilities.
The data in the present and previous studies show that vagally induced cardiac responses are inhibited after the cessation of sympathetic stimulation.9'10'30,33 The persistent sympathetic stimulation-evoked inhibition of cardiac vagal effects remains after combined a-and f3-adrenergic receptor blockade and can be mimicked by exogenous NPY, but not by exogenous norepinephrine.9"1030'33 This evidence strongly suggests that NPY, released during sympathetic activation, contributes to the persistent inhibition of cardiac vagal effects. Our data show that after the 5-and 10-Hz ansae stimulations, the time course of NPY-LI washout into the coronary sinus blood was similar in duration to the time course of the inhibition of the vagal effects on cycle length. The slow time course of NPY-LI washout from the heart indicates that NPY remains in the cardiac interstitium for a substantial time after the cessation of sympathetic activation and thereby can act on vagal nerve terminals to persistently attenuate vagally induced cardiac responses. Other mechanisms also may be responsible for the long duration of NPY action. For example, NPY may only slowly dissociate from its receptors, or NPY may initiate long-lasting postreceptor events.
The significantly elevated circulating levels of NPY-LI after sympathetic stimulation ( Figure 5 ) also may contribute to the persistent inhibition of cardiac vagal effects. Our HPLC data (Figures 7 and 8 ) suggest that after sympathetic stimulation, the circulating NPY-LI represents oxidized NPY-(1-36), fragments of NPY, and nonoxidized NPY- 
